IN2014CN02971A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02971A
IN2014CN02971A IN2971CHN2014A IN2014CN02971A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A IN 2971CHN2014 A IN2971CHN2014 A IN 2971CHN2014A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A
Authority
IN
India
Prior art keywords
formula
compound
alkyl
halo
orn
Prior art date
Application number
Other languages
English (en)
Inventor
Jo Ann Wilson
Sriram Naganathan
Matthew Pfeiffer
Neil G Andersen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2014CN02971A publication Critical patent/IN2014CN02971A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IN2971CHN2014 2011-10-20 2012-10-22 IN2014CN02971A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20
PCT/US2012/061320 WO2013059788A1 (en) 2011-10-20 2012-10-22 Process for preparing quinoline derivatives

Publications (1)

Publication Number Publication Date
IN2014CN02971A true IN2014CN02971A (enrdf_load_html_response) 2015-07-03

Family

ID=47146705

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2971CHN2014 IN2014CN02971A (enrdf_load_html_response) 2011-10-20 2012-10-22

Country Status (23)

Country Link
US (3) US9365516B2 (enrdf_load_html_response)
EP (1) EP2768796B1 (enrdf_load_html_response)
JP (2) JP6208140B2 (enrdf_load_html_response)
KR (1) KR102075371B1 (enrdf_load_html_response)
CN (2) CN110511158A (enrdf_load_html_response)
AR (1) AR088483A1 (enrdf_load_html_response)
AU (2) AU2012325768B2 (enrdf_load_html_response)
BR (1) BR112014009302B1 (enrdf_load_html_response)
CA (1) CA2852771C (enrdf_load_html_response)
DK (1) DK2768796T3 (enrdf_load_html_response)
EA (1) EA031485B1 (enrdf_load_html_response)
ES (1) ES2765013T3 (enrdf_load_html_response)
GE (1) GEP20207110B (enrdf_load_html_response)
HU (1) HUE048023T2 (enrdf_load_html_response)
IL (1) IL232139A (enrdf_load_html_response)
IN (1) IN2014CN02971A (enrdf_load_html_response)
MX (1) MX343288B (enrdf_load_html_response)
PL (1) PL2768796T3 (enrdf_load_html_response)
PT (1) PT2768796T (enrdf_load_html_response)
TW (2) TWI642650B (enrdf_load_html_response)
UA (1) UA116876C2 (enrdf_load_html_response)
WO (1) WO2013059788A1 (enrdf_load_html_response)
ZA (1) ZA201402579B (enrdf_load_html_response)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 C-met調節劑醫藥組合物
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
KR20240170977A (ko) 2011-02-10 2024-12-05 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
DK2768796T3 (da) * 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
AU2014232714B2 (en) 2013-03-15 2018-07-19 Exelixis, Inc. Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
MX384828B (es) 2014-02-14 2025-03-14 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
JP6789923B2 (ja) 2014-07-31 2020-11-25 エグゼリクシス, インコーポレイテッド フッ素18標識化カボザンチニブ及びその類似体の調製方法
CN106573042A (zh) 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 治疗多发性骨髓瘤的药物组合
US10745346B2 (en) * 2015-09-02 2020-08-18 Kuen-Feng Chen Agonists of protein tyrosine phosphatase SHP-1
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
CN117820226A (zh) 2018-01-26 2024-04-05 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
JP7409696B2 (ja) 2018-06-15 2024-01-09 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
JP2024513179A (ja) * 2021-03-24 2024-03-22 バイオコン・リミテッド カボザンチニブの調製のためのプロセス
AU2023384196A1 (en) * 2022-11-25 2025-06-12 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2466818T3 (es) 2003-09-26 2014-06-11 Exelixis, Inc. Moduladores c-Met y métodos de uso
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
JP2008537748A (ja) 2005-04-06 2008-09-25 エクセリクシス、インコーポレイテッド c−Metモジュレーター及び使用方法
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス, インコーポレイテッド Mek阻害剤の使用方法
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
UY32142A (es) * 2008-09-26 2010-05-31 Smithkline Beckman Corp Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
TW201022258A (en) * 2008-11-13 2010-06-16 Exelixis Inc Methods of preparing quinoline derivatives
EP2367795A1 (en) 2008-12-04 2011-09-28 Exelixis, Inc. Methods of preparing quinoline derivatives
KR20170052702A (ko) 2009-01-16 2017-05-12 엑셀리시스, 인코포레이티드 N-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
WO2011009095A1 (en) 2009-07-17 2011-01-20 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2011224203A1 (en) 2010-03-12 2012-10-04 Exelixis, Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
TWI619495B (zh) 2010-07-16 2018-04-01 艾克塞里克斯公司 C-met調節劑醫藥組合物
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CN103391772A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
KR20240170977A (ko) 2011-02-10 2024-12-05 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
DK2768796T3 (da) 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
BR112014011009A2 (pt) 2011-11-08 2017-06-06 Exelixis Inc inibidor duplo de met e vegf para tratar câncer
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
ES2726605T3 (es) 2012-09-07 2019-10-08 Exelixis Inc Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón

Also Published As

Publication number Publication date
US20140256938A1 (en) 2014-09-11
CN110511158A (zh) 2019-11-29
AU2012325768A1 (en) 2014-05-22
CA2852771A1 (en) 2013-04-25
NZ624328A (en) 2016-10-28
ES2765013T3 (es) 2020-06-05
AU2017254982A1 (en) 2017-11-23
CA2852771C (en) 2019-11-26
NZ723880A (en) 2018-03-23
JP2014530880A (ja) 2014-11-20
AU2012325768B2 (en) 2017-08-10
US20160229805A1 (en) 2016-08-11
JP6208140B2 (ja) 2017-10-04
IL232139A (en) 2017-11-30
JP2017222648A (ja) 2017-12-21
WO2013059788A1 (en) 2013-04-25
PL2768796T3 (pl) 2020-05-18
KR20140088874A (ko) 2014-07-11
MX343288B (es) 2016-11-01
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
TW201321342A (zh) 2013-06-01
IL232139A0 (en) 2014-05-28
BR112014009302B1 (pt) 2020-04-28
TW201731812A (zh) 2017-09-16
ZA201402579B (en) 2015-03-25
HUE048023T2 (hu) 2020-05-28
EP2768796A1 (en) 2014-08-27
TWI642650B (zh) 2018-12-01
HK1201517A1 (en) 2015-09-04
CN104395284A (zh) 2015-03-04
UA116876C2 (uk) 2018-05-25
KR102075371B1 (ko) 2020-02-10
TWI619694B (zh) 2018-04-01
EP2768796B1 (en) 2019-11-20
US20180230100A1 (en) 2018-08-16
BR112014009302A2 (pt) 2017-05-23
EA201490831A1 (ru) 2014-09-30
PT2768796T (pt) 2020-02-21
AR088483A1 (es) 2014-06-11
DK2768796T3 (da) 2020-02-24
EA031485B1 (ru) 2019-01-31
GEP20207110B (en) 2020-05-25
US9969692B2 (en) 2018-05-15
GEAP201913471A (en) 2019-10-25

Similar Documents

Publication Publication Date Title
IN2014CN02971A (enrdf_load_html_response)
MX2014006992A (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
PH12016502334B1 (en) Method for producing fused heterocyclic compound
AU2012248061C1 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
IN2014MN01521A (enrdf_load_html_response)
EP2681204A4 (en) SYNTHESIS OF INTERMEDIATE PRODUCTS FOR TREPROSTINE PRODUCTION
IN2014DN00144A (enrdf_load_html_response)
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
IN2014MN00976A (enrdf_load_html_response)
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
MY160511A (en) Synthesis of rare earth metal extractant
IN2015DN00665A (enrdf_load_html_response)
MX354498B (es) Cristal de hidrato 5-hidroxi-1h-imidazol-4-carboxamida-3/4, metodo para producir el mismo y cristal de hidrato de 5-hidroxi-1h-imidazol-4-carboxamida.
WO2011102640A3 (en) Method for preparing sitagliptin and amine salt intermediates used therein
MX2012001722A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IN2012DN00361A (enrdf_load_html_response)
MX2013008595A (es) Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina.
UA113067C2 (xx) Спосіб одержання хінолінкарбонової кислоти
UA111329C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою
IN2014CN04123A (enrdf_load_html_response)
IN2014DN05745A (enrdf_load_html_response)
BR112013018809A8 (pt) Processo para produção de derivados de ácido amidocarboxílico aromático
NZ709587A (en) Method for preparing cyclopropane derivatives
GEP20156369B (en) New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid
IN2014DN10440A (enrdf_load_html_response)